Global Influenzavirus B Infection Drug Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Influenzavirus B Infection Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Influenzavirus B Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Influenzavirus B Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Influenzavirus B Infection Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Influenzavirus B Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Influenzavirus B Infection Drug market include Sanofi, AbbVie Inc, Vectura Group Plc, Vaxart Inc, TSRL Inc, SK Chemicals Co Ltd, Shionogi & Co Ltd, Sanofi Pasteur SA and Romark Laboratories LC, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Influenzavirus B Infection Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Influenzavirus B Infection Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Influenzavirus B Infection Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Influenzavirus B Infection Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Influenzavirus B Infection Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Influenzavirus B Infection Drug sales, projected growth trends, production technology, application and end-user industry.
Influenzavirus B Infection Drug Segment by Company
Sanofi
AbbVie Inc
Vectura Group Plc
Vaxart Inc
TSRL Inc
SK Chemicals Co Ltd
Shionogi & Co Ltd
Sanofi Pasteur SA
Romark Laboratories LC
Park Active Molecules
Novavax Inc
Mucosis BV
MedImmune LLC
Medicago Inc
Kineta Inc
Inovio Pharmaceuticals Inc
Green Cross Corp
GlaxoSmithKline Plc
Fujifilm Holdings Corporation
Daiichi Sankyo Company Ltd
ContraFect Corp
Cadila Healthcare Ltd
BioCryst Pharmaceuticals Inc
Aphios Corp
Amarillo Biosciences Inc
Altravax Inc
Adimmune Corp
Influenzavirus B Infection Drug Segment by Type
KIN-1400
GC-3106A
CF-403
APP-309
Others
Influenzavirus B Infection Drug Segment by Application
Clinic
Hospital
Others
Influenzavirus B Infection Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Influenzavirus B Infection Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Influenzavirus B Infection Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Influenzavirus B Infection Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Influenzavirus B Infection Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenzavirus B Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Influenzavirus B Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenzavirus B Infection Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Influenzavirus B Infection Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Influenzavirus B Infection Drug industry.
Chapter 3: Detailed analysis of Influenzavirus B Infection Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Influenzavirus B Infection Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Influenzavirus B Infection Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Influenzavirus B Infection Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Influenzavirus B Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Influenzavirus B Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Influenzavirus B Infection Drug market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Influenzavirus B Infection Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Influenzavirus B Infection Drug market include Sanofi, AbbVie Inc, Vectura Group Plc, Vaxart Inc, TSRL Inc, SK Chemicals Co Ltd, Shionogi & Co Ltd, Sanofi Pasteur SA and Romark Laboratories LC, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Influenzavirus B Infection Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Influenzavirus B Infection Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Influenzavirus B Infection Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Influenzavirus B Infection Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Influenzavirus B Infection Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Influenzavirus B Infection Drug sales, projected growth trends, production technology, application and end-user industry.
Influenzavirus B Infection Drug Segment by Company
Sanofi
AbbVie Inc
Vectura Group Plc
Vaxart Inc
TSRL Inc
SK Chemicals Co Ltd
Shionogi & Co Ltd
Sanofi Pasteur SA
Romark Laboratories LC
Park Active Molecules
Novavax Inc
Mucosis BV
MedImmune LLC
Medicago Inc
Kineta Inc
Inovio Pharmaceuticals Inc
Green Cross Corp
GlaxoSmithKline Plc
Fujifilm Holdings Corporation
Daiichi Sankyo Company Ltd
ContraFect Corp
Cadila Healthcare Ltd
BioCryst Pharmaceuticals Inc
Aphios Corp
Amarillo Biosciences Inc
Altravax Inc
Adimmune Corp
Influenzavirus B Infection Drug Segment by Type
KIN-1400
GC-3106A
CF-403
APP-309
Others
Influenzavirus B Infection Drug Segment by Application
Clinic
Hospital
Others
Influenzavirus B Infection Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Influenzavirus B Infection Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Influenzavirus B Infection Drug market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Influenzavirus B Infection Drug significant trends, drivers, influence factors in global and regions.
6. To analyze Influenzavirus B Infection Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenzavirus B Infection Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Influenzavirus B Infection Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenzavirus B Infection Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Influenzavirus B Infection Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Influenzavirus B Infection Drug industry.
Chapter 3: Detailed analysis of Influenzavirus B Infection Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Influenzavirus B Infection Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Influenzavirus B Infection Drug in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note:Â Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
215 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Influenzavirus B Infection Drug Sales Value (2020-2031)
- 1.2.2 Global Influenzavirus B Infection Drug Sales Volume (2020-2031)
- 1.2.3 Global Influenzavirus B Infection Drug Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Influenzavirus B Infection Drug Market Dynamics
- 2.1 Influenzavirus B Infection Drug Industry Trends
- 2.2 Influenzavirus B Infection Drug Industry Drivers
- 2.3 Influenzavirus B Infection Drug Industry Opportunities and Challenges
- 2.4 Influenzavirus B Infection Drug Industry Restraints
- 3 Influenzavirus B Infection Drug Market by Company
- 3.1 Global Influenzavirus B Infection Drug Company Revenue Ranking in 2024
- 3.2 Global Influenzavirus B Infection Drug Revenue by Company (2020-2025)
- 3.3 Global Influenzavirus B Infection Drug Sales Volume by Company (2020-2025)
- 3.4 Global Influenzavirus B Infection Drug Average Price by Company (2020-2025)
- 3.5 Global Influenzavirus B Infection Drug Company Ranking (2023-2025)
- 3.6 Global Influenzavirus B Infection Drug Company Manufacturing Base and Headquarters
- 3.7 Global Influenzavirus B Infection Drug Company Product Type and Application
- 3.8 Global Influenzavirus B Infection Drug Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Influenzavirus B Infection Drug Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Influenzavirus B Infection Drug Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Influenzavirus B Infection Drug Market by Type
- 4.1 Influenzavirus B Infection Drug Type Introduction
- 4.1.1 KIN-1400
- 4.1.2 GC-3106A
- 4.1.3 CF-403
- 4.1.4 APP-309
- 4.1.5 Others
- 4.2 Global Influenzavirus B Infection Drug Sales Volume by Type
- 4.2.1 Global Influenzavirus B Infection Drug Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Influenzavirus B Infection Drug Sales Volume by Type (2020-2031)
- 4.2.3 Global Influenzavirus B Infection Drug Sales Volume Share by Type (2020-2031)
- 4.3 Global Influenzavirus B Infection Drug Sales Value by Type
- 4.3.1 Global Influenzavirus B Infection Drug Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Influenzavirus B Infection Drug Sales Value by Type (2020-2031)
- 4.3.3 Global Influenzavirus B Infection Drug Sales Value Share by Type (2020-2031)
- 5 Influenzavirus B Infection Drug Market by Application
- 5.1 Influenzavirus B Infection Drug Application Introduction
- 5.1.1 Clinic
- 5.1.2 Hospital
- 5.1.3 Others
- 5.2 Global Influenzavirus B Infection Drug Sales Volume by Application
- 5.2.1 Global Influenzavirus B Infection Drug Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Influenzavirus B Infection Drug Sales Volume by Application (2020-2031)
- 5.2.3 Global Influenzavirus B Infection Drug Sales Volume Share by Application (2020-2031)
- 5.3 Global Influenzavirus B Infection Drug Sales Value by Application
- 5.3.1 Global Influenzavirus B Infection Drug Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Influenzavirus B Infection Drug Sales Value by Application (2020-2031)
- 5.3.3 Global Influenzavirus B Infection Drug Sales Value Share by Application (2020-2031)
- 6 Influenzavirus B Infection Drug Regional Sales and Value Analysis
- 6.1 Global Influenzavirus B Infection Drug Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Influenzavirus B Infection Drug Sales by Region (2020-2031)
- 6.2.1 Global Influenzavirus B Infection Drug Sales by Region: 2020-2025
- 6.2.2 Global Influenzavirus B Infection Drug Sales by Region (2026-2031)
- 6.3 Global Influenzavirus B Infection Drug Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Influenzavirus B Infection Drug Sales Value by Region (2020-2031)
- 6.4.1 Global Influenzavirus B Infection Drug Sales Value by Region: 2020-2025
- 6.4.2 Global Influenzavirus B Infection Drug Sales Value by Region (2026-2031)
- 6.5 Global Influenzavirus B Infection Drug Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Influenzavirus B Infection Drug Sales Value (2020-2031)
- 6.6.2 North America Influenzavirus B Infection Drug Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Influenzavirus B Infection Drug Sales Value (2020-2031)
- 6.7.2 Europe Influenzavirus B Infection Drug Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Influenzavirus B Infection Drug Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Influenzavirus B Infection Drug Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Influenzavirus B Infection Drug Sales Value (2020-2031)
- 6.9.2 South America Influenzavirus B Infection Drug Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Influenzavirus B Infection Drug Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Influenzavirus B Infection Drug Sales Value Share by Country, 2024 VS 2031
- 7 Influenzavirus B Infection Drug Country-level Sales and Value Analysis
- 7.1 Global Influenzavirus B Infection Drug Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Influenzavirus B Infection Drug Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Influenzavirus B Infection Drug Sales by Country (2020-2031)
- 7.3.1 Global Influenzavirus B Infection Drug Sales by Country (2020-2025)
- 7.3.2 Global Influenzavirus B Infection Drug Sales by Country (2026-2031)
- 7.4 Global Influenzavirus B Infection Drug Sales Value by Country (2020-2031)
- 7.4.1 Global Influenzavirus B Infection Drug Sales Value by Country (2020-2025)
- 7.4.2 Global Influenzavirus B Infection Drug Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.9.2 France Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.16.2 China Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.19.2 India Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Influenzavirus B Infection Drug Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Influenzavirus B Infection Drug Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Influenzavirus B Infection Drug Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Sanofi
- 8.1.1 Sanofi Comapny Information
- 8.1.2 Sanofi Business Overview
- 8.1.3 Sanofi Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Sanofi Influenzavirus B Infection Drug Product Portfolio
- 8.1.5 Sanofi Recent Developments
- 8.2 AbbVie Inc
- 8.2.1 AbbVie Inc Comapny Information
- 8.2.2 AbbVie Inc Business Overview
- 8.2.3 AbbVie Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.2.4 AbbVie Inc Influenzavirus B Infection Drug Product Portfolio
- 8.2.5 AbbVie Inc Recent Developments
- 8.3 Vectura Group Plc
- 8.3.1 Vectura Group Plc Comapny Information
- 8.3.2 Vectura Group Plc Business Overview
- 8.3.3 Vectura Group Plc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Vectura Group Plc Influenzavirus B Infection Drug Product Portfolio
- 8.3.5 Vectura Group Plc Recent Developments
- 8.4 Vaxart Inc
- 8.4.1 Vaxart Inc Comapny Information
- 8.4.2 Vaxart Inc Business Overview
- 8.4.3 Vaxart Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Vaxart Inc Influenzavirus B Infection Drug Product Portfolio
- 8.4.5 Vaxart Inc Recent Developments
- 8.5 TSRL Inc
- 8.5.1 TSRL Inc Comapny Information
- 8.5.2 TSRL Inc Business Overview
- 8.5.3 TSRL Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.5.4 TSRL Inc Influenzavirus B Infection Drug Product Portfolio
- 8.5.5 TSRL Inc Recent Developments
- 8.6 SK Chemicals Co Ltd
- 8.6.1 SK Chemicals Co Ltd Comapny Information
- 8.6.2 SK Chemicals Co Ltd Business Overview
- 8.6.3 SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.6.4 SK Chemicals Co Ltd Influenzavirus B Infection Drug Product Portfolio
- 8.6.5 SK Chemicals Co Ltd Recent Developments
- 8.7 Shionogi & Co Ltd
- 8.7.1 Shionogi & Co Ltd Comapny Information
- 8.7.2 Shionogi & Co Ltd Business Overview
- 8.7.3 Shionogi & Co Ltd Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Shionogi & Co Ltd Influenzavirus B Infection Drug Product Portfolio
- 8.7.5 Shionogi & Co Ltd Recent Developments
- 8.8 Sanofi Pasteur SA
- 8.8.1 Sanofi Pasteur SA Comapny Information
- 8.8.2 Sanofi Pasteur SA Business Overview
- 8.8.3 Sanofi Pasteur SA Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Sanofi Pasteur SA Influenzavirus B Infection Drug Product Portfolio
- 8.8.5 Sanofi Pasteur SA Recent Developments
- 8.9 Romark Laboratories LC
- 8.9.1 Romark Laboratories LC Comapny Information
- 8.9.2 Romark Laboratories LC Business Overview
- 8.9.3 Romark Laboratories LC Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Romark Laboratories LC Influenzavirus B Infection Drug Product Portfolio
- 8.9.5 Romark Laboratories LC Recent Developments
- 8.10 Park Active Molecules
- 8.10.1 Park Active Molecules Comapny Information
- 8.10.2 Park Active Molecules Business Overview
- 8.10.3 Park Active Molecules Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Park Active Molecules Influenzavirus B Infection Drug Product Portfolio
- 8.10.5 Park Active Molecules Recent Developments
- 8.11 Novavax Inc
- 8.11.1 Novavax Inc Comapny Information
- 8.11.2 Novavax Inc Business Overview
- 8.11.3 Novavax Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.11.4 Novavax Inc Influenzavirus B Infection Drug Product Portfolio
- 8.11.5 Novavax Inc Recent Developments
- 8.12 Mucosis BV
- 8.12.1 Mucosis BV Comapny Information
- 8.12.2 Mucosis BV Business Overview
- 8.12.3 Mucosis BV Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Mucosis BV Influenzavirus B Infection Drug Product Portfolio
- 8.12.5 Mucosis BV Recent Developments
- 8.13 MedImmune LLC
- 8.13.1 MedImmune LLC Comapny Information
- 8.13.2 MedImmune LLC Business Overview
- 8.13.3 MedImmune LLC Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.13.4 MedImmune LLC Influenzavirus B Infection Drug Product Portfolio
- 8.13.5 MedImmune LLC Recent Developments
- 8.14 Medicago Inc
- 8.14.1 Medicago Inc Comapny Information
- 8.14.2 Medicago Inc Business Overview
- 8.14.3 Medicago Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.14.4 Medicago Inc Influenzavirus B Infection Drug Product Portfolio
- 8.14.5 Medicago Inc Recent Developments
- 8.15 Kineta Inc
- 8.15.1 Kineta Inc Comapny Information
- 8.15.2 Kineta Inc Business Overview
- 8.15.3 Kineta Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.15.4 Kineta Inc Influenzavirus B Infection Drug Product Portfolio
- 8.15.5 Kineta Inc Recent Developments
- 8.16 Inovio Pharmaceuticals Inc
- 8.16.1 Inovio Pharmaceuticals Inc Comapny Information
- 8.16.2 Inovio Pharmaceuticals Inc Business Overview
- 8.16.3 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.16.4 Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
- 8.16.5 Inovio Pharmaceuticals Inc Recent Developments
- 8.17 Green Cross Corp
- 8.17.1 Green Cross Corp Comapny Information
- 8.17.2 Green Cross Corp Business Overview
- 8.17.3 Green Cross Corp Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.17.4 Green Cross Corp Influenzavirus B Infection Drug Product Portfolio
- 8.17.5 Green Cross Corp Recent Developments
- 8.18 GlaxoSmithKline Plc
- 8.18.1 GlaxoSmithKline Plc Comapny Information
- 8.18.2 GlaxoSmithKline Plc Business Overview
- 8.18.3 GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.18.4 GlaxoSmithKline Plc Influenzavirus B Infection Drug Product Portfolio
- 8.18.5 GlaxoSmithKline Plc Recent Developments
- 8.19 Fujifilm Holdings Corporation
- 8.19.1 Fujifilm Holdings Corporation Comapny Information
- 8.19.2 Fujifilm Holdings Corporation Business Overview
- 8.19.3 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.19.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Product Portfolio
- 8.19.5 Fujifilm Holdings Corporation Recent Developments
- 8.20 Daiichi Sankyo Company Ltd
- 8.20.1 Daiichi Sankyo Company Ltd Comapny Information
- 8.20.2 Daiichi Sankyo Company Ltd Business Overview
- 8.20.3 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.20.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Product Portfolio
- 8.20.5 Daiichi Sankyo Company Ltd Recent Developments
- 8.21 ContraFect Corp
- 8.21.1 ContraFect Corp Comapny Information
- 8.21.2 ContraFect Corp Business Overview
- 8.21.3 ContraFect Corp Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.21.4 ContraFect Corp Influenzavirus B Infection Drug Product Portfolio
- 8.21.5 ContraFect Corp Recent Developments
- 8.22 Cadila Healthcare Ltd
- 8.22.1 Cadila Healthcare Ltd Comapny Information
- 8.22.2 Cadila Healthcare Ltd Business Overview
- 8.22.3 Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.22.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Product Portfolio
- 8.22.5 Cadila Healthcare Ltd Recent Developments
- 8.23 BioCryst Pharmaceuticals Inc
- 8.23.1 BioCryst Pharmaceuticals Inc Comapny Information
- 8.23.2 BioCryst Pharmaceuticals Inc Business Overview
- 8.23.3 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.23.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Product Portfolio
- 8.23.5 BioCryst Pharmaceuticals Inc Recent Developments
- 8.24 Aphios Corp
- 8.24.1 Aphios Corp Comapny Information
- 8.24.2 Aphios Corp Business Overview
- 8.24.3 Aphios Corp Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.24.4 Aphios Corp Influenzavirus B Infection Drug Product Portfolio
- 8.24.5 Aphios Corp Recent Developments
- 8.25 Amarillo Biosciences Inc
- 8.25.1 Amarillo Biosciences Inc Comapny Information
- 8.25.2 Amarillo Biosciences Inc Business Overview
- 8.25.3 Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.25.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Product Portfolio
- 8.25.5 Amarillo Biosciences Inc Recent Developments
- 8.26 Altravax Inc
- 8.26.1 Altravax Inc Comapny Information
- 8.26.2 Altravax Inc Business Overview
- 8.26.3 Altravax Inc Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.26.4 Altravax Inc Influenzavirus B Infection Drug Product Portfolio
- 8.26.5 Altravax Inc Recent Developments
- 8.27 Adimmune Corp
- 8.27.1 Adimmune Corp Comapny Information
- 8.27.2 Adimmune Corp Business Overview
- 8.27.3 Adimmune Corp Influenzavirus B Infection Drug Sales, Value and Gross Margin (2020-2025)
- 8.27.4 Adimmune Corp Influenzavirus B Infection Drug Product Portfolio
- 8.27.5 Adimmune Corp Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Influenzavirus B Infection Drug Value Chain Analysis
- 9.1.1 Influenzavirus B Infection Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Influenzavirus B Infection Drug Sales Mode & Process
- 9.2 Influenzavirus B Infection Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Influenzavirus B Infection Drug Distributors
- 9.2.3 Influenzavirus B Infection Drug Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
